Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Trial Details

NCT ID

NCT07368270

Phase

PHASE1

Sponsor

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Anti-PD1 armored CD19 CAR-T cells

Locations (sample)

• Suzhou, China|31.30408,120.59538

Key Eligibility Criteria

• 1\. Subjects voluntarily participate in clinical research and sign informed consent.
• 2\. Adult subjects (age ≥18 ) with relapsed or refractory diffuse large B-cell lymphoma: a) failure to achieve CR after 6 cycles, or PR after 3 cyc…
• 3\. Expected survival ≥ 3 months.
• 4\. At least one measurable lesion as per revised IWG response criteria for malignant lymphom (2014 Lugano criteria).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.